Crossmark

Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12916-022-02362-9

Published Online: 2022-05-10

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Weihua

Wan, Rui

Guo, Lei

Chang, Geyun

Jiang, Dong

Meng, Lin

Ying, Jianming
Funding

Funding for this research was provided by:

Major Research Plan (81972808)

Beijing Hope Run Special Fund of Cancer Foundation of the People’s Republic of China (LC2019L04)
License Information

Text and Data Mining valid from 2022-05-10

Version of Record valid from 2022-05-10
More Information

Article History

Received: 10 February 2022

Accepted: 4 April 2022

First Online: 10 May 2022

Declarations

:

: The study was approved by the Institutional Review Board of the Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College. Written informed consent was obtained from each patient, and the methods were carried out in accordance with approved guidelines.

: Not applicable.

: DJ and LM were employed at Beijing Novogene Bioinformatics Technology Co., Ltd. The remaining authors declare no conflict of interest.

Document is current

Any future updates will be listed below